Enzene had its new biomanufacturing facility inaugurated by Governor Phil Murphy yesterday in New Jersey, further expanding its global biotech capabilities in the US.
The new 80,000-sqft facility is located in Hopewell and represents the continuously innovative development and manufacturing organisation's (CIDMO) first major manufacturing investment in the US.
As well as fed-batch drug substance manufacturing, the site makes extensive use of the company’s modular EnzeneX 2.0 platform, which is the world’s first fully connected continuous manufacturing (FCCM) technology.
Sustainable and scalable, the platform leverages optimised cell media and process analytical technology (PAT) to achieve 10-times the yield of conventional biomanufacturing and reduce the cost of goods sold (COGS) to as low as $40 per gram.
"Their decision reflects not only our state’s strength as a hub for global business and innovation, but also the deep cultural ties that bind New Jersey and India,” said Governor Phil Murphy.
"When Enzene — one of India’s most promising biotechnological companies — decided to launch its very first US manufacturing base, they knew there was nowhere better to do it than right here in New Jersey."
“This state-of-the-art facility represents the future of advanced manufacturing — ultimately creating hundreds of jobs and generating $50m in investment. As Enzene expands its presence here in New Jersey, we remain committed to supporting the company as it builds the world-class manufacturing ecosystem of tomorrow.”
"We are proud to bring our global expertise to the US and contribute to the advancement of biopharmaceutical manufacturing,” added Himanshu Gadgil, CEO of Enzene.
“Our first-to-market manufacturing technology is forging a new path in biologics manufacturing that will provide a cost-efficient, high-yield, US-based biomanufacturing solution for biopharmaceutical innovators, and complement our facilities in India to provide global supply solutions."
Sandeep Singh, Chair of the Board at Enzene and Managing Director of Alkem Laboratories, added: “Enzene has demonstrated that it is committed to providing transformative innovations that can have a positive impact on biopharmaceutical development."
"In pioneering small-footprint, scalable biomanufacturing, Enzene is providing benefits in sustainability, cost and ultimately to the global healthcare ecosystem."
"This latest step in the company’s strategic expansion plans extends Enzene’s commitment to providing equitable access to cost-effective manufacturing for early stage biologics developers in the US and beyond.”
State and local officials, including the Mayor of Hopewell Township, Courtney Peters-Manning, First Lady of New Jersey, Tammy Murphy, and delegates from the offices of Senator Kim and Congresswoman Bonnie Watson Coleman, also attended the opening ceremony.